Pharma companies' Q1 margins likely to decline despite revenue growth: Goldman Sachs

Indian pharmaceutical firms anticipate revenue increases in the first quarter of fiscal year twenty twenty six twenty seven. Profitability is expected to decline due to an unfavorable product mix and higher input costs. The domestic market continues to show healthy growth, supported by volume and pricing improvements. US generic drug pricing remains benign, though injectable segments see monthly increases.

Raccontata daeconomictimes.indiatimes.com